• About ApaTech
• Our Vision, Culture and Values
• Company Profile
• Technology
• The Science of Actifuse
• The Evidence of Actifuse
• Actifuse Clinical Case Series
• Pipeline and Product Development

About ApaTech

ApaTech is a world leader in orthobiologics, through its development, production and sales of world-leading synthetic bone graft technology.

ApaTech specializes in producing synthetic bone repair material. It has operations in London, England, Foxborough, Massachusetts, USA and Berlin, Germany, and is a world leader in bone graft technologies, selling its products in over 30 countries around the world.

The Company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the Company’s leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth.

ApaTech is backed by international investors, Encore Ventures and Healthcor and following its formation in 2001, the Company has raised more than $60m from investors.

ApaTech is committed to delivering shareholder value by:

• Using its scientific leadership to deliver targeted solutions to physicians, allowing them to significantly improve patient outcomes
• Responsibly managing the Company's financial resources

ApaTech has received several corporate business and research awards, most recently the Frost & Sullivan ‘2009 North American Biologics Company of the Year’ as a result of its success in the US orthobiologics market. More recently, ApaTech was awarded 3rd place in the UK Deloitte Technology Fast 50 (2009), in addition to being recognized as Britain’s fastest growing medical technology company 3 years running in 2009, 2008 and 2007 by the Sunday Times (London) Fast Track 100 fastest growing private companies review.

Mission
ApaTech is committed to improving patient outcomes through development of its superior bone graft technology and application of its scientific insight, delivered with passion and ambition.

Science
Using unparalleled insight into the use of silicon in accelerating bone formation the Company has developed a new class of material which provides a range of leading edge products, that enable orthopedic and spine surgeons to improve patient outcomes in bone graft operations.

Leadership
ApaTech continues to innovate and lead scientific, clinical and commercial developments that redefine orthobiologics. Under the strong business leadership of the Board, the company continues to grow rapidly around the world.

Our story
ApaTech was spun out of Queen Mary University London in 2001 with the rights to bone materials research and IP from London and Cambridge Universities. The company retains pipeline agreements with founding inventors, including Professor William Bonfield, CBE and Queen Mary University of London. CE Mark and 510(k) clearances have been made for its first bone graft substitute ApaPore and for Actifuse, a new class of bone graft material that combines osteoconductive, osteostimulatory and bioactive activities, in a wide range of orthopedic and spinal applications.